Last reviewed · How we verify
MEDIQUE APAP EXTRA STRENGTH acetaminophen tablet, film coated (APAP)
APAP, marketed by HF Acquisition Co LLC, DBA HealthFirst, is an extra-strength acetaminophen tablet used primarily for headache relief. The drug's key strength lies in its well-established mechanism of action, effectively blocking the production of prostaglandins to alleviate pain and fever. A primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | APAP |
|---|---|
| Sponsor | HF Acquisition Co LLC, DBA HealthFirst |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Headache
- Muscular Aches
- Arthritis Pain
- Backache
- Common Cold
- Toothache
- Premenstrual and Menstrual Cramps
- Fever
Common side effects
Key clinical trials
- Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine (NA)
- Post Operative Analgesia and Patient Satisfaction
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (PHASE1,PHASE2)
- Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin (PHASE1)
- Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: